scholarly journals The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials

2018 ◽  
Vol 14 (9) ◽  
pp. 2107-2113 ◽  
Author(s):  
Ellen Suder ◽  
Wakako Furuyama ◽  
Heinz Feldmann ◽  
Andrea Marzi ◽  
Emmie de Wit
Keyword(s):  
Clinical Trials ◽  
Vesicular Stomatitis Virus ◽  
Virus Vaccine ◽  
Ebola Virus ◽  
Vesicular Stomatitis

scholarly journals High dose of Vesicular Stomatitis Virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission

2021 ◽  
pp. 1-42
Author(s):  
Igor Morozov ◽  
Thomas P. Monath ◽  
David A. Meekins ◽  
Jessie D. Trujillo ◽  
Sun-Young Sunwoo ◽  
...  
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Virus Vaccine ◽  
Ebola Virus ◽  
Horizontal Transmission ◽  
High Dose ◽  
Vesicular Stomatitis ◽  
Vesicular Disease

scholarly journals Protective Efficacy of a Bivalent Recombinant Vesicular Stomatitis Virus Vaccine in the Syrian Hamster Model of Lethal Ebola Virus Infection

2011 ◽  
Vol 204 (suppl_3) ◽  
pp. S1090-S1097 ◽  
Author(s):  
Yoshimi Tsuda ◽  
David Safronetz ◽  
Kyle Brown ◽  
Rachel LaCasse ◽  
Andrea Marzi ◽  
...  
Keyword(s):  
Virus Infection ◽  
Vesicular Stomatitis Virus ◽  
Virus Vaccine ◽  
Syrian Hamster ◽  
Ebola Virus ◽  
Protective Efficacy ◽  
Hamster Model ◽  
Vesicular Stomatitis ◽  
Ebola Virus Infection

scholarly journals Next-Generation Sequencing Reveals a Controlled Immune Response to Zaire Ebola Virus Challenge in Cynomolgus Macaques Immunized with Vesicular Stomatitis Virus Expressing Zaire Ebola Virus Glycoprotein (VSVΔG/EBOVgp)

2015 ◽  
Vol 22 (3) ◽  
pp. 354-356 ◽  
Author(s):  
Fredrik Barrenas ◽  
Richard R. Green ◽  
Matthew J. Thomas ◽  
G. Lynn Law ◽  
Sean C. Proll ◽  
...  
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Host Response ◽  
Ebola Virus ◽  
Mononuclear Cells ◽  
Transcriptional Response ◽  
Peripheral Blood Mononuclear ◽  
Virus Challenge ◽  
Cynomolgus Macaques ◽  
Vesicular Stomatitis ◽  
Generation Sequencing

ABSTRACTVesicular stomatitis virus expressing Zaire Ebola virus (EBOV) glycoprotein (VSVΔG/EBOVgp) could be used as a vaccine to meet the 2014 Ebola virus outbreak. To characterize the host response to this vaccine, we used mRNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from cynomolgus macaques after VSVΔG/EBOVgp immunization and subsequent EBOV challenge. We found a controlled transcriptional response that transitioned to immune regulation as the EBOV was cleared. This observation supports the safety of the vaccine.

scholarly journals Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors

2015 ◽  
Vol 89 (13) ◽  
pp. 6711-6724 ◽  
Author(s):  
Guido Wollmann ◽  
Eugene Drokhlyansky ◽  
John N. Davis ◽  
Connie Cepko ◽  
Anthony N. van den Pol
Keyword(s):  
Brain Tumors ◽  
Vesicular Stomatitis Virus ◽  
Brain Cancer ◽  
Ebola Virus ◽  
Marburg Virus ◽  
Chimeric Virus ◽  
Lassa Virus ◽  
Gene Coding ◽  
Vesicular Stomatitis ◽  
The Brain

ABSTRACTHigh-grade tumors in the brain are among the deadliest of cancers. Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothesis that the neurotoxicity associated with the virus could be eliminated without blocking its oncolytic potential in the brain by replacing the neurotropic VSV glycoprotein with the glycoprotein from one of five different viruses, including Ebola virus, Marburg virus, lymphocytic choriomeningitis virus (LCMV), rabies virus, and Lassa virus. Based onin vitroinfections of normal and tumor cells, we selected two viruses to testin vivo. Wild-type VSV was lethal when injected directly into the brain. In contrast, a novel chimeric virus (VSV-LASV-GPC) containing genes from both the Lassa virus glycoprotein precursor (GPC) and VSV showed no adverse actions within or outside the brain and targeted and completely destroyed brain cancer, including high-grade glioblastoma and melanoma, even in metastatic cancer models. When mice had two brain tumors, intratumoral VSV-LASV-GPC injection in one tumor (glioma or melanoma) led to complete tumor destruction; importantly, the virus moved contralaterally within the brain to selectively infect the second noninjected tumor. A chimeric virus combining VSV genes with the gene coding for the Ebola virus glycoprotein was safe in the brain and also selectively targeted brain tumors but was substantially less effective in destroying brain tumors and prolonging survival of tumor-bearing mice. A tropism for multiple cancer types combined with an exquisite tumor specificity opens a new door to widespread application of VSV-LASV-GPC as a safe and efficacious oncolytic chimeric virus within the brain.IMPORTANCEMany viruses have been tested for their ability to target and kill cancer cells. Vesicular stomatitis virus (VSV) has shown substantial promise, but a key problem is that if it enters the brain, it can generate adverse neurologic consequences, including death. We tested a series of chimeric viruses containing genes coding for VSV, together with a gene coding for the glycoprotein from other viruses, including Ebola virus, Lassa virus, LCMV, rabies virus, and Marburg virus, which was substituted for the VSV glycoprotein gene. Ebola and Lassa chimeric viruses were safe in the brain and targeted brain tumors. Lassa-VSV was particularly effective, showed no adverse side effects even when injected directly into the brain, and targeted and destroyed two different types of deadly brain cancer, including glioblastoma and melanoma.

scholarly journals Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus

2015 ◽  
Vol 212 (suppl 2) ◽  
pp. S443-S451 ◽  
Author(s):  
Demetrius Matassov ◽  
Andrea Marzi ◽  
Terri Latham ◽  
Rong Xu ◽  
Ayuko Ota-Setlik ◽  
...  
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Ebola Virus ◽  
Lethal Dose ◽  
Virus Vector ◽  
Vesicular Stomatitis

scholarly journals A Polyamide Inhibits Replication of Vesicular Stomatitis Virus by Targeting RNA in the Nucleocapsid

2018 ◽  
Vol 92 (8) ◽  
pp. e00146-18 ◽  
Author(s):  
Ryan H. Gumpper ◽  
Weike Li ◽  
Carlos H. Castañeda ◽  
M. José Scuderi ◽  
James K. Bashkin ◽  
...  
Keyword(s):  
Crystal Structure ◽  
Vesicular Stomatitis Virus ◽  
Ebola Virus ◽  
Rna Viruses ◽  
Rna Virus ◽  
Viral Rna ◽  
Negative Strand ◽  
Double Stranded Dna ◽  
Vesicular Stomatitis ◽  
Syncytial Virus

ABSTRACTPolyamides have been shown to bind double-stranded DNA by complementing the curvature of the minor groove and forming various hydrogen bonds with DNA. Several polyamide molecules have been found to have potent antiviral activities against papillomavirus, a double-stranded DNA virus. By analogy, we reason that polyamides may also interact with the structured RNA bound in the nucleocapsid of a negative-strand RNA virus. Vesicular stomatitis virus (VSV) was selected as a prototype virus to test this possibility since its genomic RNA encapsidated in the nucleocapsid forms a structure resembling one strand of an A-form RNA duplex. One polyamide molecule, UMSL1011, was found to inhibit infection of VSV. To confirm that the polyamide targeted the nucleocapsid, a nucleocapsid-like particle (NLP) was incubated with UMSL1011. The encapsidated RNA in the polyamide-treated NLP was protected from thermo-release and digestion by RNase A. UMSL1011 also inhibits viral RNA synthesis in the intracellular activity assay for the viral RNA-dependent RNA polymerase. The crystal structure revealed that UMSL1011 binds the structured RNA in the nucleocapsid. The conclusion of our studies is that the RNA in the nucleocapsid is a viable antiviral target of polyamides. Since the RNA structure in the nucleocapsid is similar in all negative-strand RNA viruses, polyamides may be optimized to target the specific RNA genome of a negative-strand RNA virus, such as respiratory syncytial virus and Ebola virus.IMPORTANCENegative-strand RNA viruses (NSVs) include several life-threatening pathogens, such as rabies virus, respiratory syncytial virus, and Ebola virus. There are no effective antiviral drugs against these viruses. Polyamides offer an exceptional opportunity because they may be optimized to target each NSV. Our studies on vesicular stomatitis virus, an NSV, demonstrated that a polyamide molecule could specifically target the viral RNA in the nucleocapsid and inhibit viral growth. The target specificity of the polyamide molecule was proved by its inhibition of thermo-release and RNA nuclease digestion of the RNA bound in a model nucleocapsid, and a crystal structure of the polyamide inside the nucleocapsid. This encouraging observation provided the proof-of-concept rationale for designing polyamides as antiviral drugs against NSVs.

scholarly journals Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates

2008 ◽  
Vol 82 (11) ◽  
pp. 5664-5668 ◽  
Author(s):  
Thomas W. Geisbert ◽  
Kathleen M. Daddario-DiCaprio ◽  
Kinola J. N. Williams ◽  
Joan B. Geisbert ◽  
Anders Leung ◽  
...  
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Rhesus Monkeys ◽  
Nonhuman Primates ◽  
Ebola Virus ◽  
Rhesus Macaques ◽  
Hemorrhagic Fever ◽  
Marburg Virus ◽  
Ebola Hemorrhagic Fever ◽  
Zaire Ebolavirus ◽  
Vesicular Stomatitis

ABSTRACT Recombinant vesicular stomatitis virus (VSV) vectors expressing homologous filoviral glycoproteins can completely protect rhesus monkeys against Marburg virus when administered after exposure and can partially protect macaques after challenge with Zaire ebolavirus. Here, we administered a VSV vector expressing the Sudan ebolavirus (SEBOV) glycoprotein to four rhesus macaques shortly after exposure to SEBOV. All four animals survived SEBOV challenge, while a control animal that received a nonspecific vector developed fulminant SEBOV hemorrhagic fever and succumbed. This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses.

Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus – Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis

Vaccine ◽  
2020 ◽  
Vol 38 (31) ◽  
pp. 4885-4891
Author(s):  
Joseph Antonello ◽  
Rebecca J. Grant-Klein ◽  
Rick Nichols ◽  
Stephen B. Kennedy ◽  
Sheri Dubey ◽  
...  
Keyword(s):  
Vesicular Stomatitis Virus ◽  
Envelope Glycoprotein ◽  
Ebola Virus ◽  
Fold Increase ◽  
Evidence Based ◽  
Virus Envelope ◽  
Vesicular Stomatitis ◽  
Cutoff Levels
Sign in / Sign up

Export Citation Format

Share Document